These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 8843302)

  • 1. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans.
    Perfect JR; Cox GM; Dodge RK; Schell WA
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1910-3. PubMed ID: 8843302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans.
    Miller JL; Schell WA; Wills EA; Toffaletti DL; Boyce M; Benjamin DK; Bartroli J; Perfect JR
    Antimicrob Agents Chemother; 2004 Feb; 48(2):384-7. PubMed ID: 14742184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-vitro and in-vivo activities of SCH56592 against Cryptococcus neoformans.
    Hossain MA; Maesaki S; Mitsutake K; Kakeya H; Sasaki E; Tomono K; Tashiro T; Kohno S
    J Antimicrob Chemother; 1999 Dec; 44(6):827-9. PubMed ID: 10590286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
    Trpković A; Pekmezović M; Barać A; Crnčević Radović L; Arsić Arsenijević V
    J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of azole resistance during fluconazole maintenance therapy for AIDS-associated cryptococcal disease.
    Friese G; Discher T; Füssle R; Schmalreck A; Lohmeyer J
    AIDS; 2001 Nov; 15(17):2344-5. PubMed ID: 11698718
    [No Abstract]   [Full Text] [Related]  

  • 6. Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates and clinical outcomes of cryptococcal meningitis in HIV-infected patients with/without fluconazole prophylaxis.
    Manosuthi W; Sungkanuparph S; Thongyen S; Chumpathat N; Eampokalap B; Thawornwan U; Foongladda S
    J Med Assoc Thai; 2006 Jun; 89(6):795-802. PubMed ID: 16850679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions between triazoles and amphotericin B against Cryptococcus neoformans.
    Barchiesi F; Schimizzi AM; Caselli F; Novelli A; Fallani S; Giannini D; Arzeni D; Di Cesare S; Di Francesco LF; Fortuna M; Giacometti A; Carle F; Mazzei T; Scalise G
    Antimicrob Agents Chemother; 2000 Sep; 44(9):2435-41. PubMed ID: 10952592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of self-assembled cationic antimicrobial peptide nanoparticles against Cryptococcus neoformans for the treatment of meningitis.
    Wang H; Xu K; Liu L; Tan JP; Chen Y; Li Y; Fan W; Wei Z; Sheng J; Yang YY; Li L
    Biomaterials; 2010 Apr; 31(10):2874-81. PubMed ID: 20044131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of dynamic characteristics of fluconazole, itraconazole, and amphotericin B against Cryptococcus neoformans using time-kill methodology.
    Burgess DS; Hastings RW
    Diagn Microbiol Infect Dis; 2000 Oct; 38(2):87-93. PubMed ID: 11035239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antifungal susceptibilities of clinical and environmental isolates of Cryptococcus neoformans in Goiânia city, Goiás, Brazil.
    Souza LK; Fernandes Ode F; Kobayashi CC; Passos XS; Costa CR; Lemos JA; Souza-Júnior AH; Silva Mdo R
    Rev Inst Med Trop Sao Paulo; 2005; 47(5):253-6. PubMed ID: 16302107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antifungal susceptibility of Cryptococcus neoformans to amphotericin B and fluconazole.
    Khyriem AB; Sujatha S; Parija SC
    Indian J Pathol Microbiol; 2006 Apr; 49(2):307-8. PubMed ID: 16933750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro susceptibility of environmental Cryptococcus neoformans variety neoformans isolates from Turkey to six antifungal agents, including SCH56592 and voriconazole.
    Yildiran ST; Saracli MA; Fothergill AW; Rinaldi MG
    Eur J Clin Microbiol Infect Dis; 2000 Apr; 19(4):317-9. PubMed ID: 10834825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina.
    Córdoba S; Isla MG; Szusz W; Vivot W; Altamirano R; Davel G
    Mycoses; 2016 Jun; 59(6):351-6. PubMed ID: 26865081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The combination of tamoxifen with amphotericin B, but not with fluconazole, has synergistic activity against the majority of clinical isolates of Cryptococcus neoformans.
    Hai TP; Van AD; Ngan NTT; Nhat LTH; Lan NPH; Vinh Chau NV; Thwaites GE; Krysan D; Day JN
    Mycoses; 2019 Sep; 62(9):818-825. PubMed ID: 31173410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotypes of clinical cerebrospinal fluid Cryptococcus neoformans isolates from southern Taiwan and their in vitro susceptibilities to amphotericin B, fluconazole, and voriconazole.
    Chang WN; Huang CR; Lei CB; Lee PY; Chien CC; Chang HW; Chang CS; Lu CH
    Jpn J Infect Dis; 2004 Jun; 57(3):113-5. PubMed ID: 15218221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo efficacy of the triazole TAK-187 against Cryptococcus neoformans.
    Schell WA; De Almeida GM; Dodge RK; Okonogi K; Perfect JR
    Antimicrob Agents Chemother; 1998 Oct; 42(10):2630-2. PubMed ID: 9756767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole.
    Casadevall A; Spitzer ED; Webb D; Rinaldi MG
    Antimicrob Agents Chemother; 1993 Jun; 37(6):1383-6. PubMed ID: 8328793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between intracranial pressure and antifungal agents levels in the CSF of patients with cryptococcal meningitis.
    Wirth F; de Azevedo MI; Pilla C; Aquino VR; Neto GW; Goldani LZ
    Med Mycol; 2018 Apr; 56(3):257-262. PubMed ID: 28992308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular epidemiology and antifungal susceptibility of Cryptococcus neoformans isolates from Ugandan AIDS patients.
    Pfaller M; Zhang J; Messer S; Tumberland M; Mbidde E; Jessup C; Ghannoum M
    Diagn Microbiol Infect Dis; 1998 Nov; 32(3):191-9. PubMed ID: 9884835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002.
    Sar B; Monchy D; Vann M; Keo C; Sarthou JL; Buisson Y
    J Antimicrob Chemother; 2004 Aug; 54(2):563-5. PubMed ID: 15254027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.